DRTS Stock: Price, Earnings History and SEC Filings
Alpha Tau Medical Ltd. (DRTS) last traded at $13.06, down 1.28% on the latest session and down 12.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.50 against an analyst estimate of $-0.14, a miss of 257.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
DRTS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-0.50 | $-0.14 | -257.14% |
| Mar 2026 | May 18, 2026 | $-0.26 | $-0.13 | -100.00% |
| Dec 2025 | Mar 9, 2026 | $-0.14 | $-0.13 | -7.69% |
| Sep 2025 | Nov 20, 2025 | $-0.14 | $-0.12 | -16.67% |
DRTS beat the analyst EPS estimate in 0 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for DRTS
Insider filing activity
DRTS insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
DRTS news
- Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock ExchangeOct 29, 2026 · finance.yahoo.com
- Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in KoreaOct 22, 2026 · finance.yahoo.com
- How Investors Are Reacting To Alpha Tau Medical (DRTS) Expanded Brain Cancer TrialOct 21, 2026 · finance.yahoo.com
- Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual MeetingOct 19, 2026 · finance.yahoo.com
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd. (DRTS) is a US-listed public company on Nasdaq. The SEC classifies its business as Surgical & Medical Instruments & Apparatus. It is incorporated in Israel. Its fiscal year ends in December.